| (Values in U.S. Thousands) | Jun, 2026 | Mar, 2026 | Dec, 2025 | Sep, 2025 | Jun, 2025 |
| Sales | 430 | 400 | 260 | 90 | 0 |
| Sales Growth | +7.50% | +53.85% | +188.89% | unch | unch |
| Net Income | -24,660 | -18,580 | -17,430 | -19,390 | -19,170 |
| Net Income Growth | -32.72% | -6.60% | +10.11% | -1.15% | -14.11% |
Pulse Biosciences CS (PLSE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Pulse Biosciences, Inc. is a medical device company. It is engaged in developing a novel and proprietary tissue treatment platform using Nano-Pulse Electro-Signaling. NPES provide effective local tumor control and to initiate an adaptive immune response. The company deploy NPES platform applications which include human oncology, dermatology, aesthetics and other minimally invasive applications. Pulse Biosciences, Inc. is based in Burlingame, California.
Fiscal Year End Date: 12/31